Stay updated on Alpelisib Plus Fulvestrant in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Alpelisib Plus Fulvestrant in Advanced Breast Cancer Clinical Trial page.

Latest updates to the Alpelisib Plus Fulvestrant in Advanced Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on advanced breast cancer, while adding a new revision number and an EudraCT number.SummaryDifference13%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.2%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check79 days agoChange DetectedThe webpage has been updated to include detailed information about a clinical study evaluating the efficacy and safety of alpelisib plus fulvestrant in treating advanced breast cancer, with specific focus on patient eligibility criteria and treatment protocols. Additionally, several clinical sites and locations have been added or modified.SummaryDifference79%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to Alpelisib Plus Fulvestrant in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpelisib Plus Fulvestrant in Advanced Breast Cancer Clinical Trial page.